NewEdge Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

NewEdge Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-31	Closed	-$96	–	3931
2023 Q4	$96	Hold	31	–	–	﹤0.01%	3643
2023 Q3	$190	Buy	+31	New	+$213	﹤0.01%	3329

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

NewEdge Advisors's PMVP Position: Q1 2024 in Review

NewEdge Advisors sold out of PMV Pharmaceuticals (PMVP) in Q1 2024, closing a stake of 31 shares — an estimated $96 sold.

NewEdge Advisors first reported a position in PMVP in Q3 2023 and held it in 2 quarters. The position peaked at $190 in Q3 2023. 99 funds tracked by Wall St. Rank hold PMVP as of Q1 2024.

NewEdge Advisors reported no remaining PMV Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
NewEdge Advisors sold 31 PMV Pharmaceuticals shares in Q1 2024, an estimated $96.
NewEdge Advisors first reported a position in PMV Pharmaceuticals in Q3 2023 and held it in 2 quarters.
NewEdge Advisors's PMV Pharmaceuticals position peaked at $190 in Q3 2023.
99 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2024.

Based on NewEdge Advisors's 13F filing for Q1 2024, filed 14 May 2024.